Verona Pharma’s Lung Disease Candidate Cuts COPD Exacerbations By 42%
Verona Pharma plc (NASDAQ:VRNA) has announced topline results from Phase 3 ENHANCE-2 of nebulized ensifentrine for the maintenance treatment of chronic…
Why These Pfizer Analysts Like The Global Blood Therapeutics Deal
Pfizer Inc. (NYSE: PFE) shares were trading lower Monday after the drugmaker announced a $5.4-billion bid to acquire blood disorder drugmaker Global Blood Therapeutics Inc (NASDAQ: GBT).
Analyst Sees This ‘Specialty Pharma’ Stock Stuck Until Prescription Trends Improve
Last week, Collegium Pharmaceutical Inc (NASDAQ:COLL) reported Q2 results—the first full quarter with BioDelivery—and beat revenue and EBITDA estimates. HC Wainwright…
Sarepta In-Licenses Next-Gen AAV Tech Covering Five Indications
Sarepta Therapeutics Inc (NASDAQ:SRPT) will license a new group of adeno-associated viruses from the institute for undisclosed upfront payment and milestone…
‘Street Underestimates Jazz Pharma’s Cash-Flow’ Says This Analyst
HC Wainwright tweaked the price target on Jazz Pharmaceuticals plc (NASDAQ:JAZZ) to $204 with a reiterated Buy rating on slightly increased forward…
Pfizer, Global Blood Therapeutics In Advanced Talks For $5B Buyout Deal: Report
Pfizer Inc (NYSE: PFE) is reportedly in advanced talks to buy Global Blood Therapeutics Inc (NASDAQ: GBT) for about $5 billion, bolster its portfolio and pipeline.
Neurocrine Biosciences Shares Jump After Raising Ingrezza Sales Guidance
Tucked in its Q2 earning release, Neurocrine Biosciences Inc (NASDAQ:NBIX) said that in August, the Phase 2a study of NBI-827104…
Voyager Therapeutics Prioritizes Pipeline With Cash Runway Into 2024
Voyager Therapeutics Inc (NASDAQ:VYGR) unveiled its prioritized therapeutic pipeline focusing on tau antibody for Alzheimer’s disease and gene therapies for GBA1…
Akebia’s Anemia Drug Disappoints In Mid-Stage COVID-19 Study
Akebia Therapeutics Inc (NASDAQ:AKBA) announced initial findings from an investigator-sponsored study evaluating vadadustat for Acute Respiratory Distress Syndrome (ARDS) with COVID-19…
Kazia Therapeutics Shares Jump On Interim Data From Paxalisib Combo Study In Brain Metastases
Kazia Therapeutics Limited (NASDAQ:KZIA) announced the presentation of new data from an ongoing phase 1 trial of paxalisib in combination with…